Navigation Links
MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
Date:10/31/2007

ward in the continued development of our product pipeline," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "Our pipeline also includes our two late stage product candidates, UDB for the treatment of pediatric asthma and MAP0004 for the treatment of migraine. We plan on initiating Phase 3 clinical programs for these two product candidates by early 2008."

Study Design

The Phase 2a clinical trial is a randomized, open-label, active-controlled, crossover, safety and dose response study investigating the pharmacokinetics and pharmacodynamics of MAP0005 in approximately 18 adult asthmatic patients. The trial compares two different doses of MAP0005 with one dose of a commercially marketed combination product, all administered by inhalation. The primary endpoints of the trial are the change in forced expiratory volume in one second (FEV1) from baseline, the time to maximum change in FEV1 and the plasma levels for the inhaled corticosteroid.

About the Tempo Inhaler

MAP Pharmaceuticals is developing the Tempo inhaler, a novel pressurized metered dose inhaler that synchronizes the discharge of drug with the patient's breathing cycle, which can be optimized for each therapy based on desired delivery. It is designed to dispense drug in an efficient and consistent manner to minimize dose-to-dose differences in and between patients. The inhaler is convenient and easy to use, and contains a dose counter that can lock out after a maximum number of doses.

About Asthma and COPD

Asthma is a chronic respiratory disorder that is characterized by inflammation and narrowing of the airways, leading to limitation or obstruction of airflow and resulting in symptoms such as episodes of wheezing, chest tightness, breathlessness and coughing. Asthma is a variable condition that can change both daily and seasonally. The Centers for Disease Control estimates there are 20 million Americans diagnosed with asthma. Despite a va
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... Hillsboro, Oregon (PRWEB) October 01, 2014 ... curing solutions , continues to expand the business worldwide. ... engineering along with additional capacity for manufacturing efforts. The ... over the last five years and expects this growth ... UV LED curing technology gains worldwide adoption. , ...
(Date:10/1/2014)... MO (PRWEB) October 01, 2014 Join the ... Castlewood Eating Disorder Treatment Center’s first ever charity golf tournament ... for people with eating disorders who cannot afford treatment. The ... Golf Club in Eureka, Mo. , The day-long event ... noon. A reception and award dinner will begin at 5 ...
(Date:10/1/2014)... October 01, 2014 Between 23 million ... the U.S., according to figures from the National Institutes ... Association (AARDA), and many of them have something else ... having undiagnosed celiac disease. Gluten Free Therapeutics, makers ... of undiagnosed celiac disease by publishing a series of ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... Financial contracts to care for sick or aging relatives ... new interest as everyday Americans wrestle with the time and ... legal expert says. , Law professor Richard L. Kaplan says ... a groundswell, and most people still bristle at the notion ...
... 27 Warner Chilcott Limited (Nasdaq: WCRX ) ... has filed for standard review the new drug application (NDA) ... NDA for WC 3016 was submitted by its subsidiary, Warner ... Warner Chilcott , Warner Chilcott is a leading ...
... Today, the Children,s Health Fund (CHF) announced a ... support a new health care clinic in the South ... Starr International Foundation grant will support the clinic,s medical ... The homeless health care clinic is part of the ...
... Inc. (OTC Bulletin Board: NVLX), an emerging healthcare ... distribute Infinitink (the world,s first permanent tattoo ink ... Zealand. The distribution agreement grants Jayhur Enterprises (Sydney, ... market, distribute and sell ...
... Kandahar, Afghanistan could help surgeons prepare for civilian disasters, ... two tours at the hospital. Dr. Vivian McAlister ... the Schulich School of Medicine & Dentistry at The ... the London Health Sciences Centre. He spent two months ...
... can lead to healthier livesST. LOUIS, May 27 ... rollout a new consumer health tool that will complement ... customers. Nurse Response will offer the Healthwise Knowledgebase, an ... Response consumers to access over 7,000 health topics online. ...
Cached Medicine News:Health News:Contracts adding legal twist to family health care 2Health News:Contracts adding legal twist to family health care 3Health News:Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive 2Health News:Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive 3Health News:Children's Health Fund Receives $500,000 from the Starr International Foundation to Support South Bronx Homeless Health Care Clinic 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 3Health News:Sharing surgical lessons from the Canadian field hospital in Afghanistan 2
(Date:9/30/2014)... 2014 STUDY OBJECTIVES The objective ... provide an overview of the current and future ... The key objective is to present a comprehensive ... an important tool in the treatment of various ... strategies within the protein therapeutics market, which includes ...
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... Group finds that the Asia Pacific dental ... , India , Japan ... implant procedure volumes will grow as physicians are increasingly trained on ... findings from Decision Resources Group,s coverage of the Asia ... implant penetration: Penetration of dental implants among the Asia ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3
... International Corporation (NASDAQ: PRXL ), a leading ... provide a live webcast of its Investor Day on ... p.m. (EDT). All interested parties are invited ... von Rickenbach, Chief Financial Officer Jim Winschel and five ...
... - Atu027, a First in Class RNAi Therapy, Demonstrates ... Possible Biomarker Identified Silence Therapeutics to Announce New ... At 2012 ASCO Annual Meeting Silence Therapeutics plc ... interference (RNAi) therapeutics company, today announces that top line data ...
Cached Medicine Technology:Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 3New Data from Silence's Atu027 Anticancer Trial Published at ASCO 4New Data from Silence's Atu027 Anticancer Trial Published at ASCO 5
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... offer a complete line of ... state-of-the-art monoclonal and monoclonal/polyclonal antibody-based ... of enteric pathogens in fecal ... for Clostridium difficile, Entamoeba histolytica, ...
Medicine Products: